Related references
Note: Only part of the references are listed.Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Patrick M. Grierson et al.
ONCOLOGIST (2023)
A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement
Naoki Ikenaga et al.
ANNALS OF SURGICAL ONCOLOGY (2023)
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
Masato Ozaka et al.
EUROPEAN JOURNAL OF CANCER (2023)
Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
Yafan Yang et al.
THORACIC CANCER (2023)
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Daniel Brock Hewitt et al.
ANNALS OF SURGERY (2022)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study
Jun Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
Annalisa Comandatore et al.
DIAGNOSTICS (2022)
Combination chemotherapy with NAB(R)-paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study)
Rachel Woodford et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma
Hani Babiker et al.
INVESTIGATIONAL NEW DRUGS (2022)
Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Niranjan Awasthi et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)
Xiaolong Yan et al.
INTERNATIONAL JOURNAL OF SURGERY (2022)
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Jun Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Neoadjuvant Therapy for Locally Advanced Esophageal Cancers
Runkai Huang et al.
FRONTIERS IN ONCOLOGY (2022)
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J. Padron et al.
NATURE MEDICINE (2022)
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study
Andrew Dean et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Daniel J. Renouf et al.
NATURE COMMUNICATIONS (2022)
Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models
Kate Crawford et al.
CANCER BIOLOGY & THERAPY (2021)
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
Naru Kondo et al.
EUROPEAN JOURNAL OF CANCER (2021)
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
M. Tempero et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
Volker Kunzmann et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
Meghan Grojean et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Guozhen Yang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
Elisa Giommoni et al.
CURRENT ONCOLOGY (2021)
Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210
Zhiyong Yang et al.
CELLULAR ONCOLOGY (2020)
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
M. Kundranda et al.
ANNALS OF ONCOLOGY (2020)
The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer
Andrew P. Barbour et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Ana De Jesus-Acosta et al.
BRITISH JOURNAL OF CANCER (2020)
HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).
Margaret A. Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation
Fengbiao Guo et al.
CANCER CELL INTERNATIONAL (2020)
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Herbert J. Zeh et al.
CLINICAL CANCER RESEARCH (2020)
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2020)
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen M. O'Reilly et al.
EUROPEAN JOURNAL OF CANCER (2020)
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
Jiali Du et al.
BIOSCIENCE REPORTS (2020)
Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303)
Daisuke Kobayashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant FOLFOX plus Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer A Brown University Oncology Research Group Phase II Study (BrUOG295)
Alexander G. Raufi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
A phase II trial of dose-reducednab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)
Shigeyuki Tamura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine andNab-Paclitaxelin Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study
Johanna Bendell et al.
ONCOLOGIST (2020)
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara et al.
LANCET ONCOLOGY (2020)
Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
Christopher Hartley et al.
PRACTICAL LABORATORY MEDICINE (2020)
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
Atsuo Takashima et al.
GASTRIC CANCER (2019)
Pharmacogenetics of treatments for pancreatic cancer
Btissame El Hassouni et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer
Niranjan Awasthi et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Rachna T. Shroff et al.
JAMA ONCOLOGY (2019)
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial
Thomas B. Karasic et al.
JAMA ONCOLOGY (2019)
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Zishuo Ian Hu et al.
CANCER MEDICINE (2019)
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)
S. Watson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
Amit Mahipal et al.
INVESTIGATIONAL NEW DRUGS (2019)
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
Olof Borga et al.
ADVANCES IN THERAPY (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors
J. S. K. Chan et al.
ONCOGENE (2018)
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
Hideaki Bando et al.
EUROPEAN JOURNAL OF CANCER (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
Md Sazzad Hassan et al.
TRANSLATIONAL ONCOLOGY (2018)
Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis
Reshma L. Mahtani et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
Wen Zhang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
Niranjan Awasthi et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial
Daquan Wang et al.
ONCOTARGETS AND THERAPY (2018)
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
Vaibhav Sahai et al.
JAMA ONCOLOGY (2018)
A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer
Sho Sato et al.
ANTICANCER RESEARCH (2018)
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial
Michele Reni et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer
M. J. Overman et al.
ANNALS OF ONCOLOGY (2018)
Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
Michel Ducreux et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
Norisuke Nakayama et al.
GASTRIC CANCER (2017)
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
Andrew H. Ko et al.
ONCOLOGIST (2017)
Pancreatic Cancer Chemoresistance to Gemcitabine
Manoj Amrutkar et al.
CANCERS (2017)
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial
Jean-Baptiste Bachet et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
The role of hypoxia in pancreatic cancer: a potential therapeutic target?
Mert Erkan et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2016)
A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma
Hua-Rong Tang et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
FOLFOX plus Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer A Brown University Oncology Research Group Phase I Study
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
N. V. Rajeshkumar et al.
BRITISH JOURNAL OF CANCER (2016)
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
Steven J. Cohen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET ONCOLOGY (2016)
Metastatic gastric cancer treatment: Second line and beyond
Marwan Ghosn et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
Hai-ying Wang et al.
ONCOTARGETS AND THERAPY (2016)
Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
Yun Fan et al.
ONCOTARGET (2016)
Molecular mechanisms of chemoresistance in gastric cancer
Wen-Jia Shi et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2015)
Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story
Joseph A. Sparano
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Madappa Kundranda et al.
Drug Design Development and Therapy (2015)
Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer
Der Sheng Sun et al.
GASTRIC CANCER (2015)
βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer
Joshua A. McCarroll et al.
ONCOTARGET (2015)
Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer
Chang Jiang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
Yasutsuna Sasaki et al.
CANCER SCIENCE (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
Roberto Iacovelli et al.
PLOS ONE (2014)
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
Peter J. Hosein et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
H. S. Kim et al.
ANNALS OF ONCOLOGY (2013)
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
Sun Jin Sym et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
SPARC and DNA methylation: Possible diagnostic and therapeutic implications in gastrointestinal cancers
Ganji Purnachandra Nagaraju et al.
CANCER LETTERS (2013)
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
Niranjan Awasthi et al.
CARCINOGENESIS (2013)
Distinct genetic aberrations in oesophageal adeno and squamous carcinoma
Ramaswamy Pandilla et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2013)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel
Jeroen J. M. A. Hendrikx et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
Chang-Hua Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
Yan Shi et al.
ONCOTARGETS AND THERAPY (2013)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
The Pancreas Cancer Microenvironment
Christine Feig et al.
CLINICAL CANCER RESEARCH (2012)
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
Hiroyuki Narahara et al.
GASTRIC CANCER (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
Neil P. Desai et al.
ANTI-CANCER DRUGS (2008)
Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma
Tine S. Mantoni et al.
CANCER BIOLOGY & THERAPY (2008)
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner et al.
CLINICAL CANCER RESEARCH (2008)
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment
Boris Blechacz et al.
HEPATOLOGY (2008)
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
S. Cereda et al.
JOURNAL OF CHEMOTHERAPY (2008)
Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience
Niraj J. Gusani et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)-free formulation of paclitaxel
Thomas E. Stinchcombe
NANOMEDICINE (2007)
In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors
Joanna M. Koziara et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Chromosomal instability, colorectal cancer and taxane resistance
Charles Swanton et al.
CELL CYCLE (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Albumin-bound paclitaxel: a next-generation taxane
William J. Gradishar
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: Randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group
MP Lutz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma
SR Park et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
M Reni et al.
LANCET ONCOLOGY (2005)
Nanostructure-mediated drug delivery
Gareth A. Hughes
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2005)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
R. Z. Yusuf et al.
CURRENT CANCER DRUG TARGETS (2003)
Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy
AJ ten Tije et al.
CLINICAL PHARMACOKINETICS (2003)
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study
BP Schneider et al.
ONCOLOGY (2003)
Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials
M Bloomston et al.
ANNALS OF SURGICAL ONCOLOGY (2002)
A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma
DP Ryan et al.
CANCER (2002)
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
P Rougier et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
